CVM
ACHAT TOTAL: 100 000 titres (~138 000,00 $ US)
- Insiders
- KERSTEN GEERT R
- Total bought
- $138,000
- Total sold
- —
- Last activity
- 2026-08-25
- Last synced
-
2026-08-31 10:14:36
Insider holdings as a share of total assets aren't available for this company.
Price (1 year)
Live chart from TradingView - pulls its own market data, independent of this site's database. Symbol resolution is best-effort (defaults to NASDAQ) since we don't store the exchange prefix.
Market snapshot
Signal
Bearish signal Scored 2026-08-28
CVM presents a meaningful insider cluster buy signal with moderate confidence (0.7), suggesting management conviction around Multikine Phase 3 data and the FDA confirmatory study pathway; however, the severely…
The first sentence of the analysis written for CVM on 2026-08-28 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Financial ratios
| Metric | Trend | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 | 2021-09-30 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Ebit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Ebitda Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Operating Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Pretax Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Continuous Operations Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Net Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Bottom Line Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Current Ratio | 2.260 | 1.312 | 1.239 | 5.454 | 11.499 | |
| Quick Ratio | 2.201 | 1.091 | 0.836 | 5.025 | 10.989 | |
| Solvency Ratio | -1.765 | -1.625 | -1.745 | -1.790 | -1.765 | |
| Cash Ratio | 2.135 | 1.027 | 0.742 | 4.861 | 9.159 | |
| Price To Earnings Ratio | -1.467 | -2.827 | -2.061 | -4.252 | -14.186 | |
| Price To Earnings Growth Ratio | 0.027 | 0.074 | 0.125 | 0.686 | -1.102 | |
| Forward Price To Earnings Growth Ratio | 0.027 | 0.074 | 0.125 | 0.686 | -1.102 | |
| Price To Earnings Diluted Ratio | -1.467 | -2.827 | -2.061 | -4.252 | -14.201 | |
| Price To Earnings Diluted Growth Ratio | 0.027 | 0.074 | 0.125 | 0.697 | -1.114 | |
| Price To Book Ratio | 2.338 | 5.898 | 5.047 | 4.974 | 9.485 | |
| Price To Sales Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Price To Free Cash Flow Ratio | -0.002 | -4.014 | -2.872 | -8.475 | -19.271 | |
| Price To Operating Cash Flow Ratio | -0.002 | -4.034 | -2.919 | -8.771 | -28.543 | |
| Debt To Assets Ratio | 0.333 | 0.431 | 0.445 | 0.303 | 0.211 | |
| Debt To Equity Ratio | 0.588 | 0.903 | 1.027 | 0.476 | 0.283 | |
| Debt To Capital Ratio | 0.370 | 0.475 | 0.507 | 0.322 | 0.220 | |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Financial Leverage Ratio | 1.764 | 2.098 | 2.310 | 1.571 | 1.342 | |
| Working Capital Turnover Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Ratio | -3,336.826 | -4.075 | -4.090 | -3.911 | -4.772 | |
| Operating Cash Flow Sales Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.002 | 1.005 | 1.016 | 1.035 | 1.481 | |
| Debt Service Coverage Ratio | -32.171 | -29.779 | -43.407 | -29.408 | -28.697 | |
| Interest Coverage Ratio | -38.231 | -35.341 | -46.602 | -33.360 | -31.493 | |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Coverage Ratio | -1,824.373 | -1.619 | -1.684 | -1.192 | -1.176 | |
| Capital Expenditure Coverage Ratio | -449.231 | -198.274 | -61.378 | -28.596 | -2.078 | |
| Dividend Paid And Capex Coverage Ratio | -449.231 | -198.274 | -61.378 | -28.596 | -2.078 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -1.712 | -3.727 | -2.596 | -4.801 | -15.650 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 0.0% | 0.0% | 0.0% |
| Ebit Margin | 0.0% | 0.0% | 0.0% |
| Ebitda Margin | 0.0% | 0.0% | 0.0% |
| Operating Profit Margin | 0.0% | 0.0% | 0.0% |
| Pretax Profit Margin | 0.0% | 0.0% | 0.0% |
| Continuous Operations Profit Margin | 0.0% | 0.0% | 0.0% |
| Net Profit Margin | 0.0% | 0.0% | 0.0% |
| Bottom Line Profit Margin | 0.0% | 0.0% | 0.0% |
| Current Ratio | 2.260 | ▲0.948 | ▼-2.092 |
| Quick Ratio | 2.201 | ▲1.110 | ▼-1.827 |
| Solvency Ratio | -1.765 | ▼-0.140 | ▼-0.027 |
| Cash Ratio | 2.135 | ▲1.108 | ▼-1.450 |
| Price To Earnings Ratio | -1.467 | ▲1.359 | ▲3.491 |
| Price To Earnings Growth Ratio | 0.027 | ▼-0.047 | ▲0.066 |
| Forward Price To Earnings Growth Ratio | 0.027 | ▼-0.047 | ▲0.066 |
| Price To Earnings Diluted Ratio | -1.467 | ▲1.359 | ▲3.494 |
| Price To Earnings Diluted Growth Ratio | 0.027 | ▼-0.047 | ▲0.066 |
| Price To Book Ratio | 2.338 | ▼-3.559 | ▼-3.210 |
| Price To Sales Ratio | 0.000 | 0.000 | 0.000 |
| Price To Free Cash Flow Ratio | -0.002 | ▲4.012 | ▲6.925 |
| Price To Operating Cash Flow Ratio | -0.002 | ▲4.032 | ▲8.852 |
| Debt To Assets Ratio | 0.333 | ▼-0.097 | ▼-0.011 |
| Debt To Equity Ratio | 0.588 | ▼-0.315 | ▼-0.067 |
| Debt To Capital Ratio | 0.370 | ▼-0.104 | ▼-0.009 |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.000 |
| Financial Leverage Ratio | 1.764 | ▼-0.333 | ▼-0.053 |
| Working Capital Turnover Ratio | 0.000 | 0.000 | 0.000 |
| Operating Cash Flow Ratio | -3336.826 | ▼-3332.750 | ▼-2666.091 |
| Operating Cash Flow Sales Ratio | 0.000 | 0.000 | 0.000 |
| Free Cash Flow Operating Cash Flow Ratio | 1.002 | ▼-0.003 | ▼-0.106 |
| Debt Service Coverage Ratio | -32.171 | ▼-2.391 | ▲0.522 |
| Interest Coverage Ratio | -38.231 | ▼-2.890 | ▼-1.226 |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Operating Cash Flow Coverage Ratio | -1824.373 | ▼-1822.754 | ▼-1458.364 |
| Capital Expenditure Coverage Ratio | -449.231 | ▼-250.957 | ▼-301.320 |
| Dividend Paid And Capex Coverage Ratio | -449.231 | ▼-250.957 | ▼-301.320 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -1.712 | ▲2.015 | ▲3.985 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $37.3M | $75.9M | $66.7M | $160.0M | $536.2M | |
| Enterprise value | $35.7M | $82.8M | $76.1M | $152.6M | $516.2M | |
| EV / Sales | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | |
| EV / Op. cash flow | -0.00x | -4.40x | -3.33x | -8.37x | -27.47x | |
| EV / Free cash flow | -0.00x | -4.38x | -3.28x | -8.08x | -18.55x | |
| EV / EBITDA | -1.71x | -3.73x | -2.60x | -4.80x | -15.65x | |
| Net debt / EBITDA | 0.07x | -0.31x | -0.32x | 0.23x | 0.61x | |
| Current ratio | 2.26x | 1.31x | 1.24x | 5.45x | 11.50x | |
| Income quality | 0.67x | 0.70x | 0.71x | 0.50x | 0.52x | |
| Graham net-net | -$0 | -$4 | -$8 | $4 | $18 | |
| Tax burden | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| Interest burden | 102.6% | 102.8% | 102.8% | 103.0% | 103.3% | |
| Working capital | $6.5M | $1.4M | $1.3M | $20.8M | $41.3M | |
| Invested capital | $12.91B | $18.6M | $22.5M | $45.7M | $70.0M | |
| Return on assets | -90.3% | -99.7% | -106.0% | -72.6% | -47.9% | |
| Operating ROA | -90.0% | -91.6% | -77.7% | -57.1% | -62.2% | |
| Return on tangible assets | -90.6% | -100.4% | -106.7% | -72.9% | -48.1% | |
| Return on equity | -159.2% | -209.2% | -244.9% | -114.1% | -64.3% | |
| Return on invested capital | -97.4% | -107.1% | -117.0% | -75.8% | -49.8% | |
| Return on capital employed | -107.8% | -117.8% | -126.2% | -78.6% | -50.3% | |
| Earnings yield | -68.1% | -35.5% | -48.5% | -22.9% | -6.8% | |
| Free cash flow yield | -45983.8% | -24.9% | -34.8% | -11.8% | -5.2% | |
| Capex / Op. cash flow | -0.2% | -0.5% | -1.6% | -3.5% | -48.1% | |
| Capex / Depreciation | 1.0% | 2.4% | 9.4% | 16.7% | 405.1% | |
| Capex / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| SG&A / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| R&D / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Stock comp / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Intangibles / Total assets | 0.4% | 0.6% | 0.6% | 0.4% | 0.4% | |
| Days sales outstanding | 0d | 0d | 0d | 0d | 0d | |
| Days payables outstanding | 24d | 133d | 33d | 0d | 0d | |
| Operating cycle | 7d | 94d | 37d | 0d | 0d | |
| Cash conversion cycle | -17d | -39d | 4d | 0d | 0d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▼-50.8%EV / Sales n/aEV / EBITDA ▲+54.1%EV / Op. cash flow ▲+4.398Earnings yield ▼-0.326
Profitability
Return on equity ▲+0.500Return on assets ▲+0.095Return on invested capital ▲+0.096Return on capital employed ▲+0.100Operating ROA ▲+0.017Income quality ▼-0.025Tax burden 0.000
Efficiency
Days sales outstanding n/aDays payables outstanding ▼-108.814Operating cycle ▼-86.821Cash conversion cycle ▲+21.993Capex / Sales n/aR&D / Sales n/a
Balance-sheet strength
Current ratio ▲+0.948Net debt / EBITDA ▲+0.385Working capital ▲+5025683.000Invested capital ▲+12890264993.000Intangibles / Total assets ▼-0.002
Change over 5 years
Valuation
Market cap ▼-93.0%EV / Sales n/aEV / EBITDA ▲+89.1%EV / Op. cash flow ▲+27.472Earnings yield ▼-0.613
Profitability
Return on equity ▼-0.949Return on assets ▼-0.423Return on invested capital ▼-0.476Return on capital employed ▼-0.574Operating ROA ▼-0.278Income quality ▲+0.157Tax burden 0.000
Efficiency
Days sales outstanding n/aDays payables outstanding n/aOperating cycle n/aCash conversion cycle n/aCapex / Sales n/aR&D / Sales n/a
Balance-sheet strength
Current ratio ▼-9.239Net debt / EBITDA ▼-0.534Working capital ▼-34868872.000Invested capital ▲+12838824457.000Intangibles / Total assets ▲+0.001
Employee count
Peer market caps
Congressional trades
No congressional trade data synced.
Recent news
- 2026-08-17 CEL-SCI Reports Fiscal Third Quarter 2026 Results VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI reported financial results for three months ended June 30, 2026, as well as key recent corporate and clinical developments for Multikine.
- 2026-08-04 CEL-SCI Study Published in Peer-Reviewed Oral Oncology Supports Multikine''s Biomarker Strategy and Potential Overall Survival Benefit Ahead of Head and Neck Cancer Confirmatory Registration Study VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI study published in peer-reviewed Oral Oncology supports Multikine''s biomarker strategy and potential overall survival benefit.
- 2026-07-30 Leading Oncology Journal Accepts For Publication New CEL-SCI Multikine Phase 3 Data Demonstrating Overall Survival Benefit in Underserved Head and Neck Cancer Patients VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--Leading oncology journal accepts for publication new CEL-SCI Multikine Phase 3 data.
- 2026-07-13 CEL-SCI to Launch FDA Registration-Enabling Phase 3 Confirmatory Study to Bring Multikine® to Market for Newly Diagnosed Head and Neck Cancer VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI to launch FDA Registration-Enabling Phase 3 Confirmatory Study to bring Multikine to Market for newly diagnosed head and neck cancer.
- 2026-06-24 CEL-SCI and Saudi Amarox Hold Strategic Agreement Signing Ceremony at BIO 2026, Advancing U.S.–Saudi Cooperation in Cancer Care VIENNA, Va.--(BUSINESS WIRE)---- $CVM #BIO2026--CEL-SCI and Saudi Amarox Hold Strategic Agreement Signing Ceremony at BIO 2026, Advancing U.S.–Saudi Cooperation in Cancer Care.
- 2026-06-16 CEL-SCI Announces Closing of Offering VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI announces closing of offering.
- 2026-06-16 CEL-SCI Advances Multikine® Immunotherapy for Head and Neck Cancer Through Dual U.S. Registration Study and Saudi Market Entry Strategy VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI advances Multikine immunotherapy for Head and Neck Cancer through dual U.S. registration study and Saudi market entry strategy.
- 2026-06-14 CEL-SCI Corporation Announces Pricing of Offering VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI Corporation announces pricing of offering.
- 2026-06-12 CEL-SCI and Saudi Amarox to Conduct Signing Ceremony at BIO 2026 for Strategic Agreement to Advance Commercialization and Distribution of Multikine® in Saudi Arabia VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI and Saudi Amarox to conduct signing ceremony at BIO 2026 for Strategic Agreement to advance commercialization and distribution of Multikine.